LONDON - Drugmaker AstraZeneca PLC says it is abandoning plans to develop a new anti-ovarian cancer drug and also says a planned antidepressant has underperformed in tests.
49396
AstraZeneca abandoning anti-ovarian cancer drug
79082
Pharmaceutical industry faces collapse
44921
Evotec enters into drug discovery collaboration with Shionogi
100995
Statins at time of surgery may improve survival in ovarian cancer
156997
Less than one percent of US women take tamoxifen to prevent breast cancer
26795
Benefits of some cancer drugs exaggerated because trials were stopped early
100390
Teva Pharmaceutical launches generic Yaz
44251
Eli Lilly halts two clinical trials of an experimental Alzheimer's treatment
155748
Drug company stands to benefit from legislation
134016
European medicines Agency recommends suspension of Avandia, Avandamet and Avaglim
37199
Bionovo (bnvi) to present positive results from phase 2 trial of Menerba
80049
Study impacts ovarian cancer treatment
1365
New drug strategy master plan being crafted --
31497
Drug stocks retreat;
127904
Pfizer ends clinical trial
16512
Nexavar in Combination with Chemotherapy Shown to Extend...
163799
AstraZeneca reports positive Phase III study